Skip to main content
    K

    Kura Oncology Inc (KURA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $7.09
    -0.68 (-8.75%)

    Market Cap: $713.90M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Kura Oncology Inc (KURA) Financials: Revenue, Profit and Cash Flow

    Updated Nov 10, 2026. Financial statements from company filings, amounts in US dollars.

    Kura Oncology reported revenue of $67.48M for the fiscal year ended Dec 31, 2025, up 25.2% from the year before. That year, net income was -$278.67M with a net margin of -412.9%, operating cash flow was -$64.06M and free cash flow was -$70.70M. The quarter ended Sep 30, 2026 had revenue of $22.84M and net income of -$70.22M.

    Revenue and Margins

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$67.48M+25.2%99.9%-449.9%-412.9%
    Dec 2024$53.88MN/A100.0%-358.5%-322.9%
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0N/AN/AN/AN/A
    Dec 2018$0N/AN/AN/AN/A
    Dec 2017$0N/AN/AN/AN/A
    Dec 2016$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$67.48M$53.88M$0$0$0$0$0$0$0$0
    Cost of revenue$57.00K$0$0$0$0$0$0$0$30.00K$0
    Gross profit$67.42M$53.88M$0$0$0$0$0$0-$30.00K$0
    Research and development$251.07M$169.97M$115.23M$92.81M$84.72M$60.40M$47.83M$46.79M$26.43M$20.40M
    Operating income-$303.63M-$193.19M-$165.80M-$139.87M-$131.26M-$91.90M-$67.48M-$62.88M-$36.08M-$28.37M
    Net income-$278.67M-$173.98M-$152.63M-$135.84M-$130.47M-$89.63M-$63.14M-$60.45M-$35.43M-$27.56M
    EBITDAN/AN/AN/A-$137.42M-$125.91M-$91.30MN/AN/A-$36.05M-$27.28M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$22.84M$20.87M$18.27M$17.34M$20.75M$15.29M$14.11M$53.88M$0$0$0$1.27M
    Gross profit$22.47M$20.63M$18.00M$17.28M$20.75M$15.29M$14.11M$53.88M$0$0$0-$214.00K
    Operating income-$74.66M-$73.01M-$78.81M-$86.27M-$80.00M-$72.67M-$64.70M-$22.45M-$59.88M-$56.40M-$54.45M-$46.76M
    Net income-$70.22M-$68.33M-$73.33M-$81.00M-$74.12M-$66.12M-$57.43M-$19.22M-$54.40M-$50.84M-$49.52M-$42.79M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded total debt of $9.71M by $139.39M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$738.36M$760.16M$448.94M$456.31M$534.05M$647.21M$241.97M$182.38M$95.85M$69.82M
    Current assets$708.66M$744.83M$432.48M$446.43M$522.29M$637.29M$239.60M$181.20M$94.64M$68.81M
    Cash and equivalents$149.10M$224.46M$37.32M$51.80M$90.67M$325.49M$26.14M$16.12M$11.43M$9.72M
    Total liabilities$564.23M$346.52M$51.66M$36.03M$27.44M$36.31M$23.19M$21.39M$15.99M$12.95M
    Short-term debt$0$2.61M$0$2.32M$2.26M$3.00M$250.00KN/A$1.53M$0
    Long-term debt$9.71M$6.92M$9.33M$9.16M$0$4.25M$7.25M$7.50M$5.57M$7.32M
    Shareholder equity$174.13M$413.64M$397.27M$420.28M$506.61M$610.90M$218.78M$160.99M$79.86M$56.88M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$566.50M$587.79M$652.55M$738.36M$649.38M$682.42M$743.76M$760.16M$478.84M$515.12M$553.91M$448.94M
    Total liabilities$548.54M$539.36M$544.67M$564.23M$406.84M$376.94M$379.36M$346.52M$55.07M$49.05M$48.82M$51.66M
    Cash and equivalents$57.94M$70.24M$39.08M$149.10M$95.29M$81.95M$51.27M$224.46M$49.48M$45.18M$41.51M$37.32M
    Shareholder equity$17.96M$48.43M$107.88M$174.13M$242.54M$305.49M$364.41M$413.64M$423.77M$466.07M$505.08M$397.27M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$64.06M$134.32M-$124.82M-$110.06M-$104.55M-$69.83M-$54.76M-$48.66M-$28.44M-$25.35M
    Capital expenditures$6.64M$472.00K$168.00K$626.00K$1.15M$2.17M$0$0$2.17M$0
    Free cash flow-$70.70M$133.84M-$124.99M-$110.69M-$105.70M-$72.00M-$54.76M-$48.66M-$30.61M-$25.35M
    Investing cash flow-$13.10M-$101.59M$15.56M$32.63M-$126.83M-$99.94M-$46.33M-$79.30M-$23.42M$12.18M
    Financing cash flow$1.79M$154.42M$94.78M$38.56M-$3.44M$469.33M$111.10M$132.64M$53.57M$7.45M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$54.44M-$62.55M-$85.85M$117.27M-$80.63M-$28.78M-$71.93M$269.13M-$43.44M-$42.53M-$48.84M-$34.31M
    Capital expenditures$445.00K$656.00K$128.00K$2.32M$2.57M$1.46M$292.00K$372.00K$0$16.00K$84.00K$16.00K
    Free cash flow-$54.89M-$63.20M-$85.98M$114.95M-$83.19M-$30.23M-$72.22M$268.76M-$43.44M-$42.55M-$48.93M-$34.32M
    Last 12 quarters

    Frequently Asked Questions About KURA

    What is Kura Oncology's annual revenue?

    Kura Oncology reported revenue of $67.48M for the fiscal year ended Dec 31, 2025.

    How fast is Kura Oncology's revenue growing?

    Revenue was up 25.2% for the fiscal year ended Dec 31, 2025 compared with the year before.

    Is Kura Oncology profitable?

    No. Kura Oncology reported net income of -$278.67M for the fiscal year ended Dec 31, 2025, with a net margin of -412.9%.

    How much free cash flow does KURA generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$64.06M minus capital expenditures of $6.64M produced free cash flow of -$70.70M.

    How much debt does Kura Oncology have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $9.71M, short-term debt of $0 and cash and equivalents of $149.10M.